Lenalidomide Sandoz 7.5 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 7.5 mg Hard Capsules, is an immunomodulatory agent presented as a 7.5 mg hard capsule for oral use. It is indicated for the treatment of adult patients with multiple myeloma and for myelodysplastic syndromes that carry the del(5q) chromosomal abnormality.

GNH USA supplies Lenalidomide Sandoz 7.5 mg Hard Capsules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related bone‑marrow disorders. - Multiple myeloma: improves progression‑free survival and overall response rates in newly diagnosed or relapsed disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission. - Relapsed or refractory multiple myeloma: provides an additional therapeutic option after prior treatments have failed.

Lenalidomide may cause a range of adverse reactions, which are typically categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count leading to infection risk. - Thrombocytopenia: low platelet count increasing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often mild to moderate.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism: clot formation in veins or lungs. - Severe skin reactions (Stevens‑Johnson syndrome): extensive rash with mucosal involvement. - Secondary primary malignancies: emergence of new cancers during therapy.

Before initiating therapy, clinicians should evaluate specific safety considerations. - Pregnancy: contraindicated (Category X); avoid use in pregnant women and ensure effective contraception. - Thromboembolic risk: assess patient history and consider prophylactic anticoagulation when risk is high. - Renal impairment: dose adjustment may be required based on measured renal function. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Lenalidomide can interact with several concomitant medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin) combined with lenalidomide in high‑risk patients: increased risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): may increase bleeding risk. - NSAIDs: may exacerbate thrombocytopenia. - P‑glycoprotein inhibitors (e.g., verapamil): may modestly increase plasma levels of lenalidomide.